SC-54684A: An orally active inhibitor of platelet aggregation

Circulation

Volumn 91, Issue 2, 1995, Pages 403-410

  Nicholson, Nancy S ^a,f   Panzer Knodle, Susan G ^a   Salyers, Anita K ^a   Taite, Beatrice B ^a   Szalony, James A ^a   Haas, Neal F ^a   King, Lucy W ^a   Zablocki, Jeffery A ^a   Keller, Bradley T ^b   Broschat, Kay ^c   Engleman, V Wayne ^c   Herin, Marc ^d   Jacqmin, Phillipe ^e   Feigen, Larry P ^a  

^a Dept of Cardiovasc Dis Research ^*  (United States)

^b Cardiovascular Diseases Research   (United States)

^c MONSANTO COMPANY   (United States)

^d Eli Lilly Benelux   (Belgium)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f PFIZER INC   (United States)

Author keywords

platelet aggregation inhibitors; platelets; thrombosis

Indexed keywords

3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; FIBRONECTIN; INTERLEUKIN 1BETA; VITRONECTIN; XEMILOFIBAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; DOG; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS;

EID: 0028895716     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.91.2.403     Document Type: Article

References (36)

1. Theroux P. Antiplatelet and antithrombotic therapy in unstable angina. Am J Cardiol. 1991;68:92B-98B.
2. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature: New Biol. 1971;231:235-237.
3. Thebault JJ, Blatri CE, Blanchard JF, Panak EA. Effects of ticlopidine, a new platelet aggregation inhibitor, in man. Clin Pharmacol Ther. 1975;18:485-491.
4. Pengo V, Boschello M, Marzari A, Baca M, Schivazappa L, Dalla-Volta S. Adenosine diphosphate (ADP)-induced alpha-granule release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thromb Haemost. 1986;56:147-150.
5. Ruggeri ZM. Von Willebrand factor as a target for antithrombotic intervention. Circulation. 1992;86(suppl III):III-26-III-29.
6. Tcheng JE, Ellis SG, Kleiman NS, Harrington RA, Mick MJ, Navetta FI, Worley S, Smith JE, Kereiakes DJ, Kitt MM, et al. Outcome of patients treated with the GPIIb/IIIa inhibitor integrelin during coronary angioplasty: results of the IMPACT Study. Circulation. 1993;88(suppl I):I-595. Abstract.
7. Schulman SP, Goldschmidt-Clermont PJ, Navetta FI, Chandra NC, Guerci AD, Califf RM, Ferguson JJ, Willerson JT, Wolfe CL, Bahr R, et al. Integrelin in unstable angina: a double-blind randomized trial. Circulation. 1993:88(suppl I):I-608. Abstract.
8. Simoons MI, van den Brand M, Hoorntije JCA, de Feytor P, Zijlstra F, Heyndricks G, van den Wieken R, De Bono D, Rutsch W, Weisman HF, et al. Chimeric 7E3 antiplatelet antibody Fab for treatment of refractory unstable angina: a placebo-controlled pilot study. J Am Coll Cardiol. 1993;21:269A. Abstract.
9. Kleiman NS, Ohman EM, Ellis SG, Aguirre FV, Weisman HP, Schaible T. Infarct vessel patency is enhanced by profound platelet inhibition with fibrinogen receptor blockade with 7E3 in patients receiving thrombolysis for acute myocardial infarction. Circulation. 1992;86(suppl I):I-260. Abstract.
10. Simoons MI, DeBoer MJ, Marcel JBM, van den Brand M, von Miltenberg AJM, Hoorntje JCA, Heyndrickx GR, van den Wieken LR, De Bono D, Rutsch W, et al. Randomized trial of a GPIIbAIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
11. Mousa SA, Bozarth JM, Forsythe MS, Jackson SM, Leamy A, Diemer MM, Kapil RP, Knabb RM, Mayo MC, Pierce SK, et al. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GP IIb/IIIa receptor antagonist. Circulation. 1994;89:3-12.
12. Nicholson NS, Panzer-Knodle SG, King LW, Taite BB, Keller BT, Tjoeng FS, Engleman VW, Giorgio TD, Feigen LP. SC-49992: a potent and specific inhibitor of platelet aggregation. Thromb Res. 1994;74:523-535.
13. Zablocki JA, Miyano M, Garland B, Pireh D, Schretzman L, Bovy P, Rico J, Lindmark RJ, Tjoeng FS, McMackins DE, et al. Fibrinogen receptor antagonists: SAR of a new orally active series. 205th ACS Meeting, Denver, Medi-3, March 29, 1993.
14. Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, King LW, Miyano M, Gorczynski RJ, Williams MH, Zupec ME, Tjoeng FS, et al. In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent. Thromb Res. 1991;62:567-578.
15. Lam SC, Plow EF, Ginsberg MH. Platelet membrane glycoprotein IIb heavy chain forms a complex with glycoprotein IIIa that binds Arg-Gly-Asp peptides. Blood. 1989;73:1513-1518.
16. Pytela R, Pierschbacher MD, Argraves S, Suzuki S, Rouslahti E. Arginine-glycine-aspartic acid adhesion receptors. Methods Enzymol. 1987;144:475-489.
17. Yatohgo T, Izumi M, Kashiwagi H, Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct. 1988;13:281-292.
18. Charo IF, Nannizzi L, Phillips DR, Hsu MA, Scarborough RM. Inhibition of fibrinogen binding to GP IIb/IIIa by a GP IIIa peptide. J Biol Chem. 1991;266:1415-1421.
19. Marguerie GA, Plow EF, Edgington TS. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem. 1979;254:5357-5363.
20. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA. 1985;82:8057-8061.
21. Look DC, Rapp SR, Keller BT, Holtzman MJ. Selective induction of intercellular adhesion molecule-1 by interferon in human airway epithelial cells. Am J Physiol. 1992;263(Lung Cell Mol Physiol 7):179-187.
22. 3 and its ligand. J Biol Chem. 1991;266:19543-19550.
23. Niiya K, Hodson E, Bader R, Byers-Ward V, Kozial JA, Plow EF, Ruggeri ZM. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation: relationships to the binding of fibrinogen and platelet aggregation. Blood. 1987;70:475-483.
24. Jergens AE, Turrentine ME, Kraus KH, Johnson GS. Buccal mucosa bleeding of healthy dogs and of dogs in various pathologic states, including thrombocytopenia, uremia, and von Willebrand's disease. Am J Vet Res. 1987;48:1337-1342.
25. Robertson T, Wright FT, Dykstra RL. Order Restricted Statistical Inference. New York: John Wiley & Sons, Ltd; 1988:180.
26. Vadas MA, Gamble JR, Smith WB. In: Harlan JM, Liu DY, eds. Adhesion: Its Role in Inflammatory Disease. New York: WH Freeman and Co; 1992:65-81.
27. Szalony JA, Haas NF, Salyers AK, Taite BB, Mehrorra DV, Feigen LP, Nicholson NS. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A Circulation. 1995;91:411-416.
28. Pytele R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glyoprotein IIb/IIIa: a member of a family of RGD specific adhesion receptors. Science. 1986;231:1559-1562.
29. Gould RJ, Varret JS, Ellis JD, Holahan MA, Stranieri MT, Theoharides AD, Lynch JJ, Friedman RA, Duggan ME, Ihle NC, et al. Characterization of L-703,014, a novel fibrinogen receptor antagonist, following oral administration to dogs. Thromb Haemost. 1993;69:539. Abstract
30. Pike NB, Foster MR, Hornby EJ, Lumley P. Effect of the fibrinogen receptor antagonist GR144053 upon platelet aggregation ex vivo following intravenous and oral administration to the Marmoset and Cynomolgus monkey. Thromb Haemost. 1993;69:1071. Abstract.
31. Conforti C, Dominguez-Jimonoz D, Zanetti A, Gimbrone MA, Cramona O, Marchisio PC, Dejana E. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood. 1992;80:437-446.
32. Coller BS, Scudder LE, Beer J, Gold HK, Foils JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, et al. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 1991;614:193-213.
33. Lind SE. The bleeding time does not predict surgical bleeding. Blood. 1991;77:2547-2552.
34. Collen D, Lu JR, Stassen J-M, Vreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time for prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost. 1994;71:95-102.
35. Jang I-K, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation. 1989;79:920-928.
36. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res. 1980;17: 841-853.